Vertex EBITDA

VRTX
 Stock
  

USD 312.22  9.10  2.83%   

Vertex Pharmaceuticals fundamentals help investors to digest information that contributes to Vertex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceuticals stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
EBITDA Margin is likely to rise to 41.49 in 2022. Enterprise Value over EBITDA is likely to rise to 374.42 in 2022.

Vertex EBITDA Analysis

Vertex Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Vertex Pharmaceuticals Earnings Before Interest Taxes and Depreciation Amortization EBITDA

3.14 Billion

EBITDA 
 = 
Revenue 
-  
Basic Expenses 
More About EBITDA | All Equity Analysis

Current Vertex Pharmaceuticals EBITDA

    
  2.92 B  
Most of Vertex Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vertex Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Vertex EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Vertex Pharmaceuticals is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as EBITDA. Since Vertex Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vertex Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vertex Pharmaceuticals' interrelated accounts and indicators.

Vertex EBITDA Historical Pattern

Today, most investors in Vertex Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vertex Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's ebitda growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Vertex Pharmaceuticals ebitda as a starting point in their analysis.
   Vertex Pharmaceuticals EBITDA   
Share
       Timeline  
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Compare to competition

Vertex EBITDA Margin

EBITDA Margin

41.49

Vertex Pharmaceuticals EBITDA Margin is fairly stable at the moment as compared to the past year. Vertex Pharmaceuticals reported EBITDA Margin of 38.45 in 2021
According to the company disclosure, Vertex Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of 2.92 B. This is 232.5% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 25.16% higher than that of the company.

Vertex EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vertex Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics of similar companies.
Vertex Pharmaceuticals is currently under evaluation in ebitda category among related companies.

Vertex Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Vertex Pharmaceuticals from analyzing Vertex Pharmaceuticals' financial statements. These drivers represent accounts that assess Vertex Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vertex Pharmaceuticals' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee114.56 K838.76 K392.27 K795.36 K600.54 K647.95 K
Revenue Per Employee1.08 M1.22 M1.39 M1.82 M1.94 M2.1 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA103.26 M706.76 M1.5 B3.26 B2.91 B3.14 B

Vertex Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Vertex Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vertex Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vertex Pharmaceuticals' value.
Security TypeSharesValue
Zwj Investment Counsel IncCommon Shares1.9 K445 K
Zwj Investment Counsel IncCommon Shares1.9 K409 K
Zweigdimenna Associates LlcCommon Shares54.1 K11.6 M
Zweigdimenna Associates LlcCommon Shares151.2 K19 M
Zweigdimenna Associates LlcCommon Shares162.2 K19.3 M
Zweigdimenna Associates LlcCommon Shares98.8 K7.9 M
Zurich Insurance Group LtdCommon Shares46.9 K7.9 M

Vertex Fundamentals

About Vertex Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
EBITDA Margin 38.45  41.49 
Enterprise Value over EBITDA 347.02  374.42 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA2.9 B3.1 B

Be your own money manager

Our tools can tell you how much better you can do entering a position in Vertex Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Transformation Now

   

Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Module

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Also, please take a look at Vertex Pharmaceuticals Piotroski F Score and Vertex Pharmaceuticals Altman Z Score analysis. You can also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for analysis

When running Vertex Pharmaceuticals price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Vertex Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.